Anti-VEGF therapy - a new hope in AMD treatment
Ana-Maria Stoica, Sanda Jurja, Nejla Dervis
TL;DR
Anti-VEGF therapy is a promising treatment for AMD by targeting blood vessel growth in the eye.
Contribution
This paper highlights the role of anti-VEGF therapy in treating AMD by inhibiting choroidal neovascularization.
Findings
VEGF inhibition has become a principal target in neovascular AMD treatment.
Intravitreal anti-VEGF agents help achieve anatomical restoration and better visual outcomes.
Sustained dosing is necessary for effective anti-VEGF therapy in AMD.
Abstract
Choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) represents a significant global cause of visual impairment. Contemporary therapeutic approaches for neovascular AMD focus on inducing regression of CNV by inhibiting critical growth factors involved in angiogenesis. For nearly two decades, vascular endothelial growth factor (VEGF) has been the principal therapeutic target, with multiple intravitreally administered agents developed to achieve anatomical restoration and improved visual outcomes through sustained dosing.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAngiogenesis and VEGF in Cancer